Changes in the density of mucosal pituitary adenylate cyclase activating peptide-27 -like immunoreactive (PACAP-27 -LI) nerve fibers within various parts of the canine gastrointestinal (GI) tract during inflammatory bowel disease (IBD) were investigated. The distribution of nerves were studied, using a single-labelling immunofluorescence technique, in the mucosal layer of canine stomach, duodenum, jejunum, and descending colon. Canine IBD caused an increase in the density of PACAP-27-LI mucosal nerves in all studied parts of GI tract. The results suggest that PACAP in the nervous system may be involved in pathological processes during IBD.
Introduction
Canine idiopathic inflammatory bowel disease (IBD) is a heterogeneous group of chronic or recurrent pathological processes within the gastrointestinal (GI) tract, which may be manifested in many ways, mainly by non-specific symptoms such as loss of appetite, vomiting, diarrhea, and weight loss (2, 16, 27) . Diagnosis of IBD is based on exclusion of other possible causes of gastrointestinal symptoms as well as on histopathological examination of the intestinal mucosal layer, where inflammatory symptoms (especially those characteristic of lymphocytic-plasmacytic enteritis) are present (2) . The pathogenesis of canine IBD remains not completely understood, although it is known that it is influenced by environmental, immunological, bacterial, and genetic factors, which make the treatment of the disease difficult and limited to dietary modifications, as well as immunosuppressive and anti-inflammatory drugs. (2, 16, 27) . Many aspects of canine IBD still remain completely unknown, for instance, the participation of active substances known as neuromediators and/or neuromodulators expressed within nervous system supplying the gastrointestinal tract in pathological processes associated with this disease. One of neuronal active substances, which seems to be an important factor involved in regulation of intestinal functions in both physiology and during pathological processes is pituitary adenylate cyclase activating peptide (PACAP) -a member of the secretin/ glucagon/vasoactive intestinal polypeptide family of peptides.
PACAP has been described for the first time in 1989 in the ovine hypothalamus as a substance, which is able to stimulate cyclic AMP formation in anterior pituitary cells (21) . It occurs in two biological forms, which are alternatively processed from a 176-amino acid precursor (preproPACAP): a 27-amino acid sequence (PACAP-27) and a C-terminally extended form PACAP-38, and shows 68% sequence homology with vasoactive intestinal polypeptide (VIP) -another very important neuromediator within the enteric nervous system (ENS) (19, 21, 32, 34) .
Both forms of PACAP have been described in the GI tract, although it is well known that PACAP-38 appears to predominate in mammalian tissues. PACAP-like immunoreactivity has been observed in neuronal structures supplying various fragments of the GI tract in numerous species, especially within elements that innervate the circular or longitudinal smooth muscle layers as well as intestinal glands (10, 14, 19, 20, 30) .
PACAP in the GI tract can play diverse functions regulated by three types of receptors (PAC1, VPAC1, VPAC2), all of which are members of the subfamily of the seven-transmembrane peptides spanning G proteincoupled receptors (30) . PACAP is involved in muscle relaxation, control of the gastric acid secretion as well as secretion of intestinal glands, and regulates proliferation within neuroendocrine cells and tumours (19) . Its role depends on animal species, segment of GI tract, and type of stimulated receptor (19, 30) .
On the other hand, both the enteric nervous system located in the wall of the digestive tract and extrinsic innervation supplying intestines are able to undergo anatomical, functional, and chemical changes as a result of adaptive or reparative processes in response to physiological and pathological stimuli, such as development or aging, diet, nerve injury, inflammatory processes, or intestinal and extra-intestinal diseases (10-13, 23, 26, 33) . Although PACAP is wellestablished enteric neuomediator and/or neuromodulator, knowledge of changes in its expression and role during intestinal pathological states is rather insufficient. Previous studies have reported changes in the number of PACAP-LI enteric neurons during Crohn's disease, carcinoma, diverticular disease in human large intestine (10, 25) , and during inflammatory processes in porcine digestive tract (14) . PACAP has been described as a powerful antiinflammatory agent, which can act by regulating the production of anti-and pro-inflammatory mediators and affects the survival and differentiation of T lymphocytes (6) . Previous studies also show protective influence of PACAP during pathological processes within the GI tract (4, 7), but the involvement of PACAP occurring within the nervous system of GI tract in such processes is ambiguous. Some studies have reported neuroprotective functions of PACAP in various parts of the nervous system (4, 22) . However, on the other hand, it does not promote the survival of neurons in myenteric plexus from the small intestine of adult rats (24) .
It should be pointed out that the majority of data, excluding single studies (14) , concern the distribution and function of PACAP-38 -the predominant form of PACAP in mammalian tissues. Moreover, knowledge of PACAP-LI nervous structures in the canine GI tract is very scarce (8, 20) and studies concerning changes in PACAP expression in the GI tract under pathological processes during IBD in this animal species have not been performed at all.
Therefore, the aim of the investigation was to describe for the first time the 27-LI nervous fibres in the mucosal layer of various segments of the canine digestive tract under physiological conditions, as well as during canine IBD, which can provide a more complete understanding of the pathological processes of this disease.
Material and Methods
The study was performed on twelve half-breed male dogs in similar age and weight (approximately 8-10 years of age and 12-18 kg b.w.). They were divided into two groups: control group (C group; n=6), which contained healthy animals, and group of dogs suffering from inflammatory bowel disease (IBD group; n=6). All experiments were performed in compliance with the instructions of the Local Ethical Committee.
Complex routine veterinary diagnostic examinations excluded any pathological status in control animals, whereas the diagnosis of IBD in animals within IBD group was based on appropriate clinical signs, such as chronic diarrhoea and/or vomiting, and weight loss for at least 3 weeks. Other chronic diseases were excluded by complete blood tests, serum biochemistry, serum trypsin-like immunoreactivity, urinalysis, parasitic and bacterial analyses of faecal samples, abdominal ultrasonography. Moreover, lymphoplasmacytic and/or eosinophilic inflammation were observed during histopathological examination of biopsies from the GI tract in all animals within IBD group. This examination was performed in the Laboratory of Histopathology (Faculty of Veterinary Medicine, University of Warmia and Mazury, Olsztyn, Poland). All dogs with IBD were scored based on the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) to assess the severity of the disease (16) and in all dogs within the IBD group, the intensity of the disease was severe or very severe (above 9 points in CCECAI scale), and signs of the disease were present in all segments of the GI tract studied.
Three samples of the mucosal layer from the same parts of the gastric fundus, duodenum, proximal part of the jejunum and the descending colon were collected from all dogs during standard pan-endoscopy and colonoscopy using a video-endoscope Olympus GIF 145 (working length 1030 mm, diameter 9.8 mm) and Olympus CF-Q165L (working length 1680, diameter 12.8 mm) and biopsy forceps FB-24U-1 (diameter 2.5 mm) or FB-50U-1 (diameter 3.7 mm).
Biopsies were fixed by immersion for 20 min in 4% buffered paraformaldehyde (pH 7.4) prepared ex tempore, rinsed in phosphate buffer (0.1 M, pH 7.4, at 4ºC) for 72 h and transferred into 18% phosphatebuffered sucrose, where they were kept at 4ºC until sectioning (at least for 5 d). Finally, biopsies were cut with a cryostat (Microm type HM525, Walldorf, Germany) at -22ºC into 10 μm sections.
Cryostat sections were processed for routine single-labelling immunofluorescence as described previously by Gonkowski et al. (11) , using antiserum directed against PACAP-27 (rabbit polyclonal, Phoenix Pharmaceuticals, USA, diluted 1:20,000). This antibody was visualised by species-specific secondary antibody conjugated to biotin (Jackson Immunochemicals, USA, diluted 1:800) and a streptavidin-CY3 complex (Jackson, diluted 1:8000). The standard specificity tests of antibody, i.e. preabsorption of the neuropeptide antiserum with appropriate antigen, omission, and replacement of primary antiserum by non-immune serum were performed to test the antibodies and specificity of the method. The pre-absorption was performed as follows: sections of biopsies were incubated with "working" dilution of PACAP antibody, which was pre-absorbed for 18 h at 37 C with 20 μg of human PACAP-27 peptide (Phoenix Pharmaceuticals, USA). This procedure, as well as omission and replacement of primary antiserum by non-immune serum, completely eliminated specific staining.
The determination of the density of PACAP-27-LI nerves was performed by two independent investigators and based on the semi-quantitative evaluation on three sections (located at least 100 µm apart from each other) from each biopsy and segment of the GI tract. Data (in total from nine sections of each segment of the digestive tract) obtained from each investigator were added up and averaged. In arbitrary scale used during this investigation, (-) means the absence of nerve fibers, (+) -single nerve fibers, (++) -rare nerve fibers, (+++) -dense meshwork of fibers, and (++++) depicted a very dense meshwork of fibers.
Results
PACAP 27-positive nerve fibers in the mucosal layer were observed within all segments of canine digestive tract studied under physiological conditions and during IBD (Table 1 ; Fig. 1 ). In control dogs, the density of such fibers fluctuated from rare (++) in the stomach (Fig. 1A) , duodenum (Fig. 1B) , and jejunum (Fig. 1C) to single (+) within the descending colon (Fig. 1D) . Inflammatory bowel disease caused an increase in the density of PACAP 27-LI mucosal nerve fibers in all parts of the digestive tract (Table 1 ; Fig. 1 ). These changes were most visible in the mucosal layer of the duodenum (Fig. 1 B) and jejunum (Fig. 1C) , where during IBD PACAP-27 -LI nerve fibers formed very dense network (++++). The smallest density of fibers in dogs with IBD was observed, like in control animals within the descending colon, where only rare (++) nerve processes immunoreactive to PACAP 27 were noted (Fig. 1D ). Clear differences in the appearance of nerve processes were observed in the particular part of canine gastrointestinal tract. Namely, in both control animals and dogs with IBD, PACAP-27 -positive mucosal nerves in the stomach, duodenum, and jejunum were predominantly delicate and thin ( Fig. 1  A, B, C) , and within the descending colon such fibers were thick (Fig. 1D) . Moreover, in control group and in animals with IBD, no visible differences in the density of fibers between particular dogs were noted.
Discussion
The results obtained during the study demonstrated that PACAP 27-LI nerve fibers are present within the mucosal layer of all studied parts of the canine digestive tract. As a result they confirm previous studies, where expression of PACAP has been described in the GI tract of various species, including humans (8, 10, 14, 19, 20) , and suggest that also in dog this peptide plays, known in other species, important multiple biological functions for optimal functioning of the gastrointestinal tract. Its role has been shown in processes, such as the gut motility, regulation of neurotransmitter release, as well as secretion of the gastric and intestinal glands (6, 19, 29, 30) . On the other hand, in spite of the fact of well-established function of PACAP in the GI tract (19) , the number of the enteric PACAP-27-LI neurons under physiological conditions generally noted in the study was relatively low, especially in small and large intestine, what confirms previous studies, which demonstrated that PACAP is the predominant form in mammalian tissues (19) .
The density of PACAP 27-LI mucosal nerve fibers clearly depends on the segment of the GI tract. The density backward declines and the smallest number of such fibers is observed in descending colon. It suggests that the exact functions of PACAP in canine digestive tract under physiological conditions are different in particular segments of intestines, what is in agreement with previous studies on other species (19, 29, 30) .
Moreover, in the study, changes in the number of PACAP 27-LI mucosal nerve fibers were observed during canine IBD and they depended on the segment of the GI tract, which strongly suggests both the participation of PACAP in adaptive and/or reparative processes during IBD, as well as the relationship between the functions of PACAP during IBD and the part of the GI tract.
An increase in the density of PACAP 27-LI nerve fibers during pathological processes connected with IBD, on one hand, may arise from the augmentation of PACAP-27 synthesis as an adaptive process in the GI tract, on the other hand, it could also indicate an increase in the PACAP-27 transport from neuronal cell body to its peripheral parts and release of this peptide from nerve endings. The observed differences in PACAP expression between control animals and dogs with IBD may be related to relatively well known anti-inflammatory and immune modulatory activity of PACAP, which has been previously described as a regulator of production of anti-and pro-inflammatory mediators, as well as a substance stimulating many macrophage functions, such as migration, adherence, phagocytosis, and superoxide production (6) . It is more probable that immunological factors play an important role in pathogenesis of canine IBD (2, 27) . The next reason of changes in PACAP expression during IBD can be the participation of this peptide in the intestinal secretion and homeostatic mechanisms connected with fluid and ion regulatory processes that undergo changes during IBD. It is in accordance with previous investigations, where PACAP-27 has been described as a factor, which activates ion transport within the small intestine in rats and is more potent than PACAP-38, as well as being a potent activator of ion transport in the human GI tract IA IIA IB IIB IC IIC ID IID (9) . Moreover, PACAP-27 in connection with the functions mentioned above, may be a contributory factor in diarrhoea during Crohn's disease (9) . The above mentioned functions of PACAP are confirmed by powerful anti-inflammatory activity of exogenously administered PACAP or its analogues (in spite of their poor metabolic stability) during various experimental models of human diseases in rodents, such as brain ischaemia, collagen-induced arthritis, or multiple sclerosis (1, 5) .
Changes in PACAP-27-like immunoreactivity observed in the study may also be connected with the functions of PACAP in the transmission of nociceptive information. PACAP is thought to be an important sensory neuropeptide, which was described in the superficial spinal horn layers and in neurons of the dorsal root ganglia (17, 22) and can play a role in conduction of sensory stimuli in pain reactions during various pathological processes (15) . On the other hand, it is well known that IBD may lead to severe and longlasting pain (3, 27) .
Moreover, observed changes in expression of PACAP 27 in mucosal nerve fibers may be due to injury of nerve endings during processes connected with IBD and neuroprotective properties of PACAP. It is well-known that injury to neurons causes an increase in the expression of neurotransmitters, which promote the regeneration of injured cells. Previous studies have documented the ability of PACAP to prevent apoptotic cell death and protect cortical neurons against glutamate-induced cytotoxity, dopaminergic neurons against 6-hydroxydopamine-induced cytotoxicity, cerebellar granule neurons against ethanol, an oxidative stress inducing cell death, as well as cerebral neurons during ischaemia (28) (29) (30) . It is also known that PACAP (mainly via PAC1 receptor) affects proliferation of neurons, axon regeneration, and development of the nervous system (3). It also plays an important role in the protection of non-neuronal tissues, such as the heart, kidneys, or olfactory epithelium, where it protects cells against inflammatory cytokine TNFα -inducing cell death (18, 19, 30) . These facts, with an increase in PACAP-27-like immunoreactivity in the enteric nervous system after axotomy observed in previous studies (14) , suggest that this peptide also plays a neuroprotective role in the ENS. However, it is not exactly clear because PACAP, unlike VIP, does not promote the survival of adult rat neurons from myenteric plexus of intestine in a culture (24) . Moreover, the differences in the PACAP-27-like immunoreactivity between particular kinds of previously studied pathological processes strongly suggest that the role of this substance depends on the character of the acting factor (14) .
To sum up, the results obtained in this study suggest the participation of PACAP 27 and mucosal nerve fibers immunoreactive to this peptide in regulatory processes in canine digestive tract, not only under physiological conditions, but also during IBD.
Involvement of PACAP 27 in pathological processes during canine IBD is probably mainly connected with functions of this substance as an anti-and/or proinflammatory factor. The obtained results may initiate a new chapter in the treatment of this disease, i.e. the utilization of PACAP and/or its analogues, which might be applied in the future not only during experimental models of human diseases in rodents (1, 5) , but also in dogs with IBD. However, such application of PACAP encounters various difficulties, the major of which is poor metabolic stability of this peptide (1, 5) . Thus, nowadays the utilization of PACAP and its analogues during treatment of canine IBD requires further systematic in vivo and in vitro investigations.
